Search results for "Adverse effect"

showing 10 items of 1065 documents

Safety of agalsidase alfa in patients with Fabry disease under 7 years

2011

Aim:  To evaluate the safety and explore the efficacy of enzyme replacement therapy (ERT) for Fabry disease with agalsidase alfa in young children enrolled in the Fabry Outcome Survey (FOS). Methods:  This retrospective chart review identified eight children (mean age = 5.0 ± 1.6 [mean ± SD]) in FOS who began treatment with agalsidase alfa (0.2 mg/kg, i.v., every other week) when <7 years old. Vital signs and adverse events were monitored throughout the study period. Glomerular filtration rate (GFR) was estimated, and left ventricular mass indexed to height2.7 (LVMi) was assessed with echocardiography. Patients received 1.2–6.7 years of treatment (mean = 4.2 years). Results:  Infusion react…

medicine.medical_specialtyVascular diseasebusiness.industryOrgan dysfunctionVital signsRenal functionRetrospective cohort studyGeneral MedicineEnzyme replacement therapymedicine.diseaseFabry diseaseSurgeryInternal medicinePediatrics Perinatology and Child Healthmedicinemedicine.symptomAdverse effectbusinessActa Paediatrica
researchProduct

Oral Propranolol for Circumscribed Choroidal Hemangioma

2011

Introduction: Several therapeutic approaches have been developed to treat choroidal hemangioma. However, all these therapies are associated with a potential risk of damaging the overlying retina. Case Report: We report a case of circumscribed choroidal hemangioma (CCH) in a 59-year-old man refractory to laser treatment. Visual acuity was 20/200 and a serous macular detachment was present. The CCH was treated with oral propanolol, whereupon visual acuity improved to 20/20 and the macular detachment resolved without systemic or local adverse effects. Discussion: Propanolol is a β-blocker commonly used in cardiology that may induce endothelium vasoconstriction and inhibit endothelial prolifera…

medicine.medical_specialtyVisual acuityEndotheliumCircumscribed choroidal hemangiomaPropranololβ-Blockerlcsh:OphthalmologyOphthalmologymedicineCircumscribed choroidal hemangiomaAdverse effectRetinaEndothelial proliferationbusiness.industry&#0946;-Blockereye diseasesSurgeryOphthalmologyPublished: February 2011medicine.anatomical_structurelcsh:RE1-994sense organsmedicine.symptombusinessVasoconstrictionmedicine.drugPropanololCase Reports in Ophthalmology
researchProduct

RheoNet Registry Analysis of Rheopheresis for Microcirculatory Disorders With a Focus on Age-Related Macular Degeneration

2010

The purpose of establishing the RheoNet registry was to evaluate the safety and efficacy of rheopheresis, a specific method of therapeutic apheresis used to treat microcirculatory disorders. Apheresis centers providing rheopheresis therapy and physicians caring for the underlying disease were asked to participate in the registry, and the registry data were analyzed for safety and tolerability. Age-related macular degeneration (AMD) was selected as a model disease to evaluate efficacy. The RheoNet registry was successfully established recording 7722 rheopheresis treatments of 1110 patients, including 833 AMD patients. The mean age of patients was 72 years. Adverse events (AE) were reported i…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryRheopheresisHematologyMacular degenerationmedicine.diseaseeye diseasesSurgeryApheresisTolerabilityNephrologyAge relatedInternal medicinemedicinemedicine.symptomAdverse effectbusinessTherapeutic apheresisTherapeutic Apheresis and Dialysis
researchProduct

Vulvo-vaginal atrophy: A new treatment modality using thermo-ablative fractional CO2 laser.

2015

a b s t r a c t Objective: To evaluate the efficacy and feasibility of thermo-ablative fractional CO2 laser for the treatment of symptoms related to vulvo-vaginal atrophy (VVA) in post-menopausal women. Methods: From April 2013 to December 2013, post-menopausal patients who complained of one or more VVA-related symptoms and who underwent vaginal treatment with fractional CO2 laser were enrolled in the study. At baseline (T0) and 30 days post-treatment (T1), vaginal status of the women was evaluated using the Vaginal Health Index (VHI), and subjective intensity of VVA symptoms was evaluated using a visual analog scale (VAS). At T1, treatment satisfaction was evaluated using a 5-point Likert …

medicine.medical_specialtyVisual analogue scaleVaginal DiseasesPilot ProjectsGeneral Biochemistry Genetics and Molecular BiologyVulvaAtrophyQuality of lifeLaser treatmentAblative casemedicineHumansAdverse effectbusiness.industryObstetrics and GynecologyMiddle Agedmedicine.diseaseSettore MED/40 - Ginecologia E OstetriciaSurgeryMenopausePostmenopauseAdministration IntravaginalDyspareuniaTreatment OutcomeLasers GasQuality of LifeItchingFemaleVaginal atrophyLaser Therapymedicine.symptomAtrophyMenopausebusinessVulvo-vaginal atrophy
researchProduct

Preventive Analgesia with Pregabalin in Neuropathic Pain from “Failed Back Surgery Syndrome”: Assessment of Sleep Quality and Disability

2015

Objective. Pregabalin group (PGB) is an antiepileptic used to treat neuropathic pain. We evaluated analgesic efficacy and safety for postoperative/chronic pain, disability, and sleep quality in patients who underwent spine surgery administered with PGB, or not, during the presurgical and postsurgical periods. Design. Retrospective cohort study of 60 patients (two groups with 30 patients) with full information on 50 (29 with PGB and 21 without PGB). Ten patients were dismissed as information was lacking. The PGB group (P) (29 patients) received 75 mg/12 hours before surgery, 150 mg 10 hours after surgery, and 150 mg/12 hours 3 days after surgery. The control group (C; 21 patients) took no PG…

medicine.medical_specialtyVisual analogue scalebusiness.industryAnalgesicChronic painPregabalinGeneral Medicinemedicine.diseaseSurgeryPreventive analgesiaOswestry Disability IndexAnesthesiology and Pain MedicineAnesthesiaNeuropathic painmedicineNeurology (clinical)businessAdverse effectmedicine.drugPain Medicine
researchProduct

Long-term, open-labeled extension study of idursulfase in the treatment of Hunter syndrome.

2011

Purpose: This study evaluated the safety and effectiveness of long-term enzyme replacement therapy with idursulfase (recombinant human iduronate-2-sulfatase) in patients with Hunter syndrome. Methods: All 94 patients who completed a 53-week double-blinded study of idursulfase enrolled in this open-labeled extension study and received intravenous idursulfase at a dose of 0.5 mg/kg weekly for 2 years, and clinical outcomes and safety were assessed. Results: No change in percent predicted forced vital capacity was seen, but absolute forced vital capacity demonstrated sustained improvement and was increased 25.1% at the end of the study. Statistically significant increases in 6-minute walking t…

medicine.medical_specialtyVital capacityAdolescentIdursulfaseIduronate SulfatasePulmonary function testingInternal medicineMedicineHumansEnzyme Replacement TherapyMucopolysaccharidosis type IIAdverse effectChildInfusions IntravenousGenetics (clinical)GlycosaminoglycansMucopolysaccharidosis IIbusiness.industryPercent Predicted Forced Vital CapacityHunter syndromeEnzyme replacement therapyOrgan Sizemedicine.diseaseSurgeryTreatment OutcomeLiverChild PreschoolbusinessSpleenmedicine.drugGenetics in medicine : official journal of the American College of Medical Genetics
researchProduct

The relevance of depressive symptoms for the outcome of patients receiving vitamin K antagonists: results from the thrombEVAL cohort study.

2020

Abstract Aims Although depressive symptoms are highly prevalent in patients receiving oral anticoagulation (OAC), the relevance of depression for the outcome of anticoagulated individuals is unknown. Methods and results We analysed data from the multicentre cohort study thrombEVAL (NCT01809015) investigating the efficacy of OAC with vitamin K antagonists. There was an independent study monitoring, and an independent review panel assessed the endpoints. Out of n = 1558 participants, information about depressive symptoms, as measured by the two-item screener of the patient health questionnaire (PHQ-2), was available in n = 1405 individuals. The mean follow-up period was 28.04 months, with a s…

medicine.medical_specialtyVitamin KProportional hazards modelbusiness.industryDepressionHazard ratioAnticoagulantsVitamin kConfidence intervalPatient Health QuestionnaireCohort StudiesInternal medicineThromboembolismmedicineHumansPharmacology (medical)Cardiology and Cardiovascular MedicineAdverse effectbusinessDepression (differential diagnoses)Cohort studyEuropean heart journal. Cardiovascular pharmacotherapy
researchProduct

OP0062-HPR Efficacy of Tailored Exercise Therapy in Patients with Knee Osteoarthritis and Comorbidity: A Randomized Controlled Trial

2016

Background Exercise therapy is a key intervention in the management of knee osteoarthritis (OA). It is an effective intervention to improve physical functioning and reduce joint pain in patients with knee OA. Comorbidity, which is highly prevalent in OA, interferes with the application of exercise therapy and contributes to non-adherence to exercise therapy. Objectives To evaluate the efficacy and safety of tailored exercise therapy on physical functioning in patients with knee osteoarthritis (OA) and comorbidity Methods A randomized clinical controlled trial was performed, comparing comorbidity-adapted exercise therapy with a control intervention. The study was conducted in an outpatient r…

medicine.medical_specialtyWOMACbusiness.industryImmunologyOsteoarthritismedicine.diseaseComorbidityGeneral Biochemistry Genetics and Molecular Biologylaw.inventionRheumatologyRandomized controlled triallawRating scaleJoint painHeart failuremedicinePhysical therapyImmunology and Allergymedicine.symptomAdverse effectbusinessAnnals of the Rheumatic Diseases
researchProduct

Clinical Development of Mepolizumab for the Treatment of Severe Eosinophilic Asthma: On the Path to Personalized Medicine.

2021

The development of mepolizumab, an anti-IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma, is an example of a clinical development program that evolved over time based on sound, basic scientific principles. Initial clinical data on the effects of mepolizumab on lung function in a general asthmatic population were disappointing. However, it became clear that mepolizumab may be more effective against other clinical endpoints, particularly asthma exacerbations, in patients with more severe disease. Furthermore, a developing understanding of asthma disease pathobiology led to the identification of an appropriate target population and predictive biomarker for mepolizumab t…

medicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationDiseaseAntibodies Monoclonal Humanized03 medical and health sciences0302 clinical medicineClinical endpointImmunology and AllergyMedicineHumans030212 general & internal medicineAnti-Asthmatic AgentsPrecision MedicineIntensive care medicineAdverse effecteducationComputingMilieux_MISCELLANEOUSAsthmaeducation.field_of_studybusiness.industrymedicine.diseaseAsthmaEosinophils030228 respiratory systemAsthma Control QuestionnairePersonalized medicinebusinessMepolizumabmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwi…

2016

Background: Interleukin (IL)-1 inhibitors have been suggested as possible therapeutic options in a large number of old and new clinical entities characterized by an IL-1 driven pathogenesis. Objectives: To perform a nationwide snapshot of the on-label and off-label use of anakinra (ANA) and canakinumab (CAN) for different conditions both in children and adults. Methods: We retrospectively collected demographic, clinical, and therapeutic data from both adult and pediatric patients treated with IL-1 inhibitors from January 2008 to July 2016. Results: Five hundred and twenty-six treatment courses given to 475 patients (195 males, 280 females; 111 children and 364 adults) were evaluated. ANA wa…

medicine.medical_specialtyautoinflammatory disorders treatment interleukin (IL)-1 anakinra canakinumabDoseanakinra; autoinflammatory disorders; canakinumab; interleukin (IL)-1; treatmentautoinflammatory disorders; treatment; interleukin (IL)-1; anakinra; canakinumab030204 cardiovascular system & hematologyOff-label usecanakinumab03 medical and health sciencesSettore MED/38 - Pediatria Generale E Specialistica0302 clinical medicineInternal medicinemedicinePharmacology (medical)Interleukin-1 inhibitorsAdverse effectOriginal Research030203 arthritis & rheumatologyPharmacologyAnakinratreatmentbusiness.industrylcsh:RM1-950Anakinra; Autoinflammatory disorders; Canakinumab; Interleukin (IL)-1; Treatment; Pharmacology; Pharmacology (medical)InterleukinRetrospective cohort studySurgeryinterleukin (IL)-1Canakinumablcsh:Therapeutics. PharmacologyAutoinflammatory disorderSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAautoinflammatory disordersAntirheumatic drugsbusinessmedicine.druganakinra
researchProduct